ABX311

ABX311 is an experimental small-molecule antiviral discovered by Abivax for the treatment of chikungunya virus infection, developed from the company’s antiviral platform of targeted small molecules that modulate viral replication pathways.[3][5][7][9][11] It was supported by non-dilutive funding from Bpifrance’s “Invest in the Future” program and advanced through preclinical development, but was subsequently placed on hold and its overall R&D status is now listed as discontinued, reflecting the lack of recent chikungunya outbreaks and shifting portfolio priorities.[3][5][9] Detailed molecular target and mechanism of action have not been publicly disclosed, other than its categorization as a small-molecule antiviral against chikungunya virus.[3][5][7][11]